Dapagliflozine can Induce and Maintain Type-2 Diabetes Remission | Abstract
Internal Medicine: Open Access

Internal Medicine: Open Access
Open Access

ISSN: 2165-8048


Dapagliflozine can Induce and Maintain Type-2 Diabetes Remission

Mahmoud Younis

Introduction: Type 2 diabetes mellitus, has gained a lot of attention in recent years as one of the most important chronic progressive diseases in the world, which slowly crawls towards longevity and which involves many chronic complications, which are dangerous to health and the economy. Sodium-glucose cotransporter-2 (SGLT2) inhibitors represent a category of newly discovered drugs that work by preventing glucose reabsorption in the proximal renal tubules. (SGLT2) inhibitors may induce type 2 diabetes remission. Design: Randomized, -controlled trial, 6-month trial.

Materials and Methods: 100 type 2 diabetes patients were randomized into 2 groups.

Results: The results show a statistically significant decrease of A1C levels after 3 and 6 months treatment with dapagliflozin and significant change in A1C levels after 3 months treatment of glimepiride but a no significant change in the next 3 months. The results also show a statistically significant decrease in BMI in the dapagliflozin group after 6 months of treatment.

Conclusion: As type 2 diabetes is one of the most disabling diseases, it is necessary to find a drug that can lead to remission. Dapagliflozin can lead to type 2 diabetes remission

Published Date: 2020-08-07; Received Date: 2020-06-08